top of page
Search

Are Mergers and Acquisitions Reshaping India’s Healthcare and Pharma Sector? Key Trends and Legal Insights


India’s healthcare and pharma industries are witnessing a powerful wave of mergers and acquisitions — but what’s fueling this boom, and what legal roadblocks lie ahead?

In recent years, India’s healthcare and pharmaceutical industries are undergoing Mergers and Acquisitions (M&A), reflecting global investment interest and domestic consolidation. This post examines the key trends driving this wave from hospital chains and specialty clinics to pharma and MedTech startups and explains the legal framework that regulate such deals. It also discusses the regulatory hurdles that acquirers face in this highly controlled industry, competition law filings, foreign investment caps, sector-specific licenses, environmental rules, pricing controls, etc. The blog outlines recent government initiatives that aim to encourage investment. In conclusion blog offers a forward-looking view on how Mergers and Acquisitions (M&A) works, if well-regulated, could strengthen India’s healthcare ecosystem.


Merges and Acquistions

Merges and Acquistions (hereinafter referred to as M&A) mean the two or more different companies are joining together become as one company. For example, Company A, B and C are the different companies. If all the three companies A, B, C are jointly becoming a new Company D then it is called merger. If Company A & B are jointly become together as Company A, then it is called Acquistions. To simplify it, M&A mean one company buying another company. These processes are used to grow the business, enter to new business or gain better technological innovation. In India such transactions are regulated by Companies Act, 2013 and may need approval form regulators like Competition Commission of India (hereinafter referred to as CCI) & Securities and Exchange Board of India (hereinafter referred to as SEBI).  In the health care and pharmaceutical sector, M&A helps companies expand hospital networks, improve access to medicines, or build digital health services. These deals often involve checking if licences, drug approvals, and safety standards are in place. Since the medical and pharmaceutical sector is highly regulated, every M&A must carefully follow the laws related to drugs, clinical facilities and patient care.


Growing Deals in Indian Healthcare and Pharma

Over the last few years, deals in India’s healthcare and pharmaceuticals sector have picked up pace. Analysts note that the first half of 2024 alone saw over $4 billion in deal value, roughly a 57% jump from a year earlier. Likewise, the first quarter of 2024 had 24 announced M&A transactions worth about $456 million. Such activity is higher than the Asia-Pacific average, and deal values are rising even if deal counts dip slightly. This uptick is driven by sustained demand (India’s hospital industry is adding tens of thousands of beds and expecting 12–14% revenue growth in 2024 and by overseas investors seeking growth. 


Example of Big M&A Deal, in April 2023 Singapore’s Temasek bought an additional stake in Manipal Hospitals (raising its total to 59%) in a $3.6 billion deal - one of the largest ever in Indian health services. In tech and pharma, Tata Digital acquired majority ownership of 1mg (an e-pharmacy platform), and Lupin Limited acquired US-based women’s health company Symbiomix for $150 million. In 3rd Quarter of 2024, India’s pharma sector alone saw 31 M&A deals (totaling $2.3 billion), including a $1.6 billion acquisition of Bharat Serums by Mankind Pharma. These and other transactions signal that large Indian hospital chains, diagnostic lab companies, pharma manufacturers, and HealthTech startups are all targets of consolidation.


Key Trends Driving Healthcare M&A


4.1 Hospital and Clinic Consolidation

Indian private hospitals are expanding aggressively. Larger chains are acquiring smaller or standalone hospitals to add beds and geographic reach. Specialty clinics are in focus too: investors are targeting single-specialty hospitals like oncology, ophthalmology, nephrology, fertility, etc., because of their strong unit economics. Over the next five years, private hospital groups plan to invest ₹32,500 crore to add roughly 30,000 new beds. In short, expect bigger, coast-to-coast hospital networks.


4.2 Digital Health and Telemedicine

The COVID-19 pandemic jump-started telemedicine and HealthTech in India. Digital health startups that are teleconsultation platforms, AI diagnostics, online pharmacies have drawn funding and strategic tie-ups. According to Deloitte and other reports, 2023 saw a wave of deals in telemedicine and biotech as investors sought tech-enabled care. The government’s Ayushman Bharat Digital Mission is also creating a national digital health platform, encouraging private players to build interoperable solutions. 


 4.3 MedTech and Devices

Private Equity firms and corporate investors are bullish on medical devices like surgical, diagnostic, wearables and health-tech hardware. Foreign investment up to 100% is now allowed in most medical device manufacturing, and the Indian MedTech market is projected to reach $50 billion in the next few years. We see traditional device makers acquiring smaller tech-savvy firms to add AI, robotics, or IoT capabilities, and vice versa.


4.4 Pharmaceutical and Biotech Focus

India is long known as the pharmacy of the world, and global players still see value in Indian drugmakers. Pharma M&A has involved big players adding portfolio breadth or entering novel areas. For instance, deals are happening in high-growth specialty areas like biosimilars and women’s health. Generic drug companies are also consolidating, there’s been increased interest in India’s bulk drug manufacturers, partly due to supply chain shifts away from China. The availability of capital for biotech and pharma research has encouraged partnerships and mergers to build Research and Development capacity.

 

4.5 Preventive and Wellness Sector

As consumers spend more on health monitoring and prevention, diagnostics chains and wellness companies are attractive M&A targets. Diagnostic labs are expanding regionally through acquisitions. Wearable health devices like smartwatches, glucose monitors and nutraceutical firms are also part of the M&A radar. The government is even considering bringing nutraceuticals under drug regulation, which could further spur deals in that area.


Legal and Regulatory Framework

Mergers and acquisitions (M&A) in India are guided by several laws. The Companies Act, 2013 is a primary act to regulate M&A. It states any merger, or demerger must be approved by the National Company Law Tribunal (NCLT). Deals are usually done through share purchase or business transfer agreements. Big transaction (M&A) required clearance from the Competition Commission of India (CCI) under the Competition Act, 2002 to ensure they don't affect the market competition. Foreign Investment rules under Foreign Exchange Management Act, 1999 allows 100% of the automatic Foreign Direct Investment (FDI) in the new pharma projects and upto 74% existing pharma ventures, but for more than 74% needs a government approval.


If company is a listed company, then the regulations of SEBI are applicable. Acquiring a significant ownership share may require an open offer. Transactions in the healthcare and pharmaceutical sectors also require specific approvals, such as drug licenses in accordance with the Drugs and Cosmetics Act, quality accreditations, environmental permissions, and legitimate intellectual property rights. Each of these legal requirements is essential for a seamless M&A process.


Key Drivers and Government Initiatives

One of the main drivers is technology companies aim to expand in fields such as telemedicine, AI-driven diagnostics, and digital record-keeping. Consequently, larger firms frequently acquire tech startups to swiftly enhance their offerings. In the pharmaceutical sector, M&A allows companies to gain access to innovative research, patented medications, or vaccines. The government's initiatives to foster innovation through incentives for research and development and policies like the National Policy on Pharma MedTech R&D encourage this trend.


The government has simplified the process of approval for the businesses by implementing speedy procedures and a single-window approach, it has led to a rise on M&A. Initiatives like Production Linked Incentive (PLI) and tax exemption are also promoting the investment in the healthcare Sector. Regarding digital initiatives, projects like the Ayushman Bharat Digital Mission are establishing a national health data infrastructure. This development could make private health-tech firms, particularly those linked to this network, appealing to potential buyers. Simultaneously, as India’s middle class expands and increases its spending more on healthcare, private hospitals and clinics are looking to expand by merging with or acquiring others.


Impact on India’s Healthcare and Pharma

Merges and Acquisitions are making changes in the Healthcare and Pharma Sectors in India. The existing big hospital groups are expanding their service into the smaller cities to provide quality care everywhere. Pharma industries and companies are joining hands to promote exports and to compete globally. When the Merged companies can be able to invest in research & development and it reduce the costs due to sharing the investment. Patients may benefit from the better services and due to less competition in the sector may lead to higher prices for services rendered. Cross border deals may bring the expertise by integration of staffs, management system and culture remains a major challenge. If M&A handled well, it led to strengthen the healthcare system in India.


India’s healthcare and pharma sectors are seeing a clear rise in mergers and acquisitions, supported by strong growth and helpful government policies. The companies are still dealing with the many rules from the drug licenses to foreign investment limits and so on. The recent reforms are making process of such deals into much easier. I believe this trend is good for the country's economic growth. It will improve the infrastructures, promote the innovation, better service, effective management system and it may raise the presence of India in the global pharma sector. However, it’s important to simplify approvals and ensure that licences continue smoothly after a deal. With the right balance of regulation and business freedom, these mergers can create stronger healthcare networks that serve more people effectively.


REFERENCES

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page